Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units.
Andrea LavinioAri ErcoleDenise BattagliniSandra MagnoniRafael BadenesFabio Silvio TacconeRaimund HelbokWilliam ThomasPaolo PelosiChiara Robbanull nullPublished in: Critical care (London, England) (2021)
In a cohort of critically ill patients with a high prevalence of thromboembolic events, ET was associated with reduced ICU mortality without an increased burden of haemorrhagic complications. This study suggests ET strategies are safe and associated with favourable outcomes. Whilst full anticoagulation has been questioned for prophylaxis in these patients, our results suggest that there may nevertheless be a role for enhanced / intermediate levels of prophylaxis. Clinical trials investigating causal relationship between intermediate thromboprophylaxis and clinical outcomes are urgently needed.
Keyphrases
- intensive care unit
- venous thromboembolism
- clinical trial
- sars cov
- end stage renal disease
- atrial fibrillation
- risk factors
- ejection fraction
- newly diagnosed
- chronic kidney disease
- coronavirus disease
- direct oral anticoagulants
- prognostic factors
- mechanical ventilation
- peritoneal dialysis
- randomized controlled trial
- coronary artery disease
- acute respiratory distress syndrome
- phase ii
- extracorporeal membrane oxygenation